English
Home > Products > Tazobactam acid API

China Tazobactam acid API Factory

Responsible excellent and fantastic credit rating standing are our principles, which will help us at a top-ranking position. Adhering towards the tenet of "quality initial, buyer supreme" for Tazobactam acid API,CAS NO:89786-04-9,Tazobactam API,Tazobactam acid,Tazobactam, Our tenet is evident each of the time: to provide good quality solution at competitive rate to clients throughout the planet. We welcome potential purchasers to call us for OEM and ODM orders.
Tazobactam acid API, Due to our dedication, our products are well known throughout the world and our export volume continuously grows every year. We will continue to strive for excellence by providing high quality products that will exceed the expectation of our customers.

Related Products

Hot Products

  • Apixaban

    Apixaban

    Product Name:Apixaban
    Molecular Formula:C25H25N5O4
    Molecular Weight;459.5
    CAS Registry Number;503612-47-3
  • 1-Methylcyclopropane-1-carboxylic acid

    1-Methylcyclopropane-1-carboxylic acid

    Product Name:1-Methylcyclopropane-1-carboxylic acid
    Molecular Formula:C5H8O2
    Molecular Weight:100.12
    CAS Registry Number:6914-76-7
  • Progesterone soft capsules

    Progesterone soft capsules

    Product Name:Progesterone soft capsules
    Dosage:0.1g
    Application:Progestins
  • (αR)-α-(2-Chlorophenyl)-2H-tetrazole-2-ethanol

    (αR)-α-(2-Chlorophenyl)-2H-tetrazole-2-ethanol

    Product Name:(αR)-α-(2-Chlorophenyl)-2H-tetrazole-2-ethanol
    Molecular Formula:C9H9ClN4O
    Molecular Weight:224.65
    CAS Registry Number:1259059-77-2
  • 5-Azacytosine

    5-Azacytosine

    Product Name:5-Azacytosine
    Molecular Formula:C3H4N4O
    Molecular Weight:112.09
    CAS Registry Number:931-86-2
  • Sodium sulfate

    Sodium sulfate

    Product Name:Sodium sulfate
    Molecular Formula:Na2SO4
    Molecular Weight;142.04214
    CAS Registry Number;7757-82-6
  • Related Blog
  • Reviews

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept